- mab: Bamlanivimab
  num_ref: 32
  num_fold: 243
  avail: EUA
  class: RBM Class II
  pdb: 7KMG
  institute: Eli Lilly
- mab: Etesevimab
  num_ref: 35
  num_fold: 380
  avail: EUA
  class: RBM Class I
  pdb: 7C01
  institute: Eli Lilly
- mab: Casirivimab
  num_ref: 47
  num_fold: 432
  avail: EUA
  class: RBM Class I
  pdb: 6XDG
  institute: Regeneron
- mab: Imdevimab
  num_ref: 47
  num_fold: 431
  avail: EUA
  class: RBD Core Cluster I
  pdb: 6XDG
  institute: Regeneron
- mab: Sotrovimab
  num_ref: 29
  num_fold: 369
  avail: EUA
  class: RBD Core Cluster I
  pdb: 6WPS
  institute: Vir Biotechnol / GlaxoSmithKline
- mab: Cilgavimab
  num_ref: 22
  num_fold: 127
  avail: Completed phase III
  class: RBM Class II
  pdb: 7L7E
  institute: AstraZeneca / Vanderbilt
- mab: Tixagevimab
  num_ref: 21
  num_fold: 108
  avail: Completed phase III
  class: RBM Class I
  pdb: 7L7E
  institute: AstraZeneca / Vanderbilt
- mab: Amubarvimab
  num_ref: 7
  num_fold: 198
  avail: Approved in China
  class: RBM Class I
  pdb: 7CDI
  institute: BRII Biosciences
- mab: Romlusevimab
  num_ref: 4
  num_fold: 94
  avail: Approved in China
  class: RBD Core Cluster II
  pdb: ''
  institute: BRII Biosciences
- mab: Regdanvimab
  num_ref: 10
  num_fold: 31
  avail: Appoved in South Korea
  class: RBM Class I
  pdb: 7CM4
  institute: Celltrion
